Skip to main content
Premium Trial:

Request an Annual Quote

Microlytic Gets $3.5M VC Investment

NEW YORK (GenomeWeb News) – Microlytic, a Copenhagen, Denmark-based protein crystallization tools firm, announced today that it has raised $3.5 million in venture capital funding.

The firm, which also has operations in Boston, plans to use the funds to expand sales and production of products for the structural biology market. It makes the Crystal Former device for crystallizing proteins and MCSG Screens, a set of crystallization reagents.

Funding was provided by Danish investment firms CAT Science Park and Vaekstfonden.

Jesper Roested, investment director of Vaekstfonden, has been named chairman of the board of Microlytic.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.